Evidence map›Paper›PMID 34082797›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.

Upasana Ray, Debarshi Roy, Ling Jin, Prabhu Thirusangu, Julie Staub, Yinan Xiao, Eleftheria Kalogera, Andrea E Wahner Hendrickson, Grace D Cullen, Krista Goergen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. The Phospholipase AJournal of lipid and atherosclerosis · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Upasana RayDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Debarshi RoyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Ling JinDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Prabhu ThirusanguDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Julie StaubDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Yinan XiaoDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Eleftheria KalogeraDivision of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA.
Andrea E Wahner HendricksonDepartment of Internal Medicine, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Grace D CullenDepartment of Internal Medicine, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Krista GoergenDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Ann L ObergDepartment of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Viji ShridharDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. shridhar.vijayalakshmi@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
NCI NIH HHS P50 CA136393NIH HHS P50CA136393
6 · The paper itself

Abstract

backgroundAberrant lipogenicity and deregulated autophagy are common in most advanced human cancer and therapeutic strategies to exploit these pathways are currently under consideration. Group III Phospholipase A2 (sPLA2-III/PLA2G3), an atypical secretory PLA2, is recognized as a regulator of lipid metabolism associated with oncogenesis. Though recent studies reveal that high PLA2G3 expression significantly correlates with poor prognosis in several cancers, however, role of PLA2G3 in ovarian cancer (OC) pathogenesis is still undetermined.

methodsCRISPR-Cas9 and shRNA mediated knockout and knockdown of PLA2G3 in OC cells were used to evaluate lipid droplet (LD) biogenesis by confocal and Transmission electron microscopy analysis, and the cell viability and sensitization of the cells to platinum-mediated cytotoxicity by MTT assay. Regulation of primary ciliation by PLA2G3 downregulation both genetically and by metabolic inhibitor PFK-158 induced autophagy was assessed by immunofluorescence-based confocal analysis and immunoblot. Transient transfection with GFP-RFP-LC3B and confocal analysis was used to assess the autophagic flux in OC cells. PLA2G3 knockout OVCAR5 xenograft in combination with carboplatin on tumor growth and metastasis was assessed in vivo. Efficacy of PFK158 alone and with platinum drugs was determined in patient-derived primary ascites cultures expressing PLA2G3 by MTT assay and immunoblot analysis.

resultsDownregulation of PLA2G3 in OVCAR8 and 5 cells inhibited LD biogenesis, decreased growth and sensitized cells to platinum drug mediated cytotoxicity in vitro and in in vivo OVCAR5 xenograft. PLA2G3 knockdown in HeyA8MDR-resistant cells showed sensitivity to carboplatin treatment. We found that both PFK158 inhibitor-mediated and genetic downregulation of PLA2G3 resulted in increased number of percent ciliated cells and inhibited cancer progression. Mechanistically, we found that PFK158-induced autophagy targeted PLA2G3 to restore primary cilia in OC cells. Of clinical relevance, PFK158 also induces percent ciliated cells in human-derived primary ascites cells and reduces cell viability with sensitization to chemotherapy.

conclusionsTaken together, our study for the first time emphasizes the role of PLA2G3 in regulating the OC metastasis. This study further suggests the therapeutic potential of targeting phospholipases and/or restoration of PC for future OC treatment and the critical role of PLA2G3 in regulating ciliary function by coordinating interface between lipogenesis and metastasis.

Indexed as

AnimalsAutophagyCell ProliferationCell SurvivalCRISPR-Cas SystemsFemaleGene Expression Regulation, NeoplasticGroup III Phospholipases A2HeterograftsHumansLipid DropletsLipogenesisMiceMicroscopy, Electron, TransmissionNeoplasm MetastasisOvarian NeoplasmsGroup III Phospholipases A2PFK158PLA2G3 protein, humanPlatinumPyridinesQuinolinesautophagychemosensitivityGroup III phospholipase A2metastasisOvarian cancerprimary cilia

Identifiers

PMID34082797
PMCPMC8173968
OpenAlexW3165178673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.